Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Patrys.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Health & Biotech
Health Check: Farewell, adieu as Argent Biopharma holders back ASX delisting
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Patrys and Next Science jump after presenting data on studies
Health & Biotech
ASX Health Stocks: Patrys to commence Phase 1 trial as drug production process put in motion
News
In Case You Missed It: Lithium takes the lead, followed by biotech and manganese today
Health & Biotech
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
News
Top 10 at 10: These ASX lithium, gas and biotech stocks are Hump Day heroes
Health & Biotech
ASX Health Stocks: Patrys crashes after Phase 1 delayed till 2024, Nova Eye surges 20pc on FDA OK
Health & Biotech
ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity
Health & Biotech
ASX Health Stocks: Patrys crosses brain barrier, opens up possibilities for its deoxymab antibody
News
Top 10 at 10: The popular ASX stocks rising above Monday’s madness
News
Market Highlight: ASX stares down dark hole as Wall St tumbles, and 5 ASX small caps to watch on Monday
Health & Biotech
ASX Health Stocks: Immutep now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug
Health & Biotech
ASX Health Stocks: Patrys wins fresh grant, IDT does not and Next Science is off to sell stuff in Canada
Health & Biotech
ASX Health Stocks: Patrys says brain cancer drug is effective; HitIQ awarded Aussie patent
News
